<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; sustainable</title>
	<atom:link href="http://www.tapanray.in/tag/sustainable/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Collaboration For Sustainable Excellence – The Name of The Game in The New Normal</title>
		<link>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal</link>
		<comments>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 May 2023 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[digital tools]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new therapeutics]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10785</guid>
		<description><![CDATA[The union minister of health and family welfare of India recently invited Japanese companies to collaborate with Indian companies on research and innovation in emerging therapies, like precision medicine, cell and gene therapy, biological products, and on the utilization of &#8230; <a href="http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/collaboration-for-sustainable-excellence-the-name-of-the-game-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing: The New Normal: Challenges of Change</title>
		<link>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-the-new-normal-challenges-of-change</link>
		<comments>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/#comments</comments>
		<pubDate>Mon, 28 Jun 2021 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[challenges of change]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[end-point]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price-point]]></category>
		<category><![CDATA[Problem-solving]]></category>
		<category><![CDATA[purpose-driven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resilience]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10537</guid>
		<description><![CDATA[A lot has changed in healthcare marketing prompted by the Covid pandemic. Apace with these, lots of old problems continue to remain very much the same. The aforesaid was observed in a recent article, published by WARC, on May 21, 2021. Although, &#8230; <a href="http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Taming Two Critical Covid Uncertainties For Pharma’s Sustainable Growth</title>
		<link>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth</link>
		<comments>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/#comments</comments>
		<pubDate>Mon, 28 Sep 2020 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cinvid-19]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infections]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[mutating]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pace-setting]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Taming]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[uncertainties]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10275</guid>
		<description><![CDATA[The reasons behind a great urgency of the Governments, besides high expectations of the general public, to have the ‘ultimate solution’ very soon, against the ongoing pandemic, are understandable. However, various media-hyped narratives on their clinical trials, and timeframe for &#8230; <a href="http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Therapy Price: Commercial Viability And Moral Dilemma</title>
		<link>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gene-therapy-price-commercial-viability-and-moral-dilemma</link>
		<comments>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/#comments</comments>
		<pubDate>Mon, 17 Jun 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercially]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moral]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spinraza]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[viability.]]></category>
		<category><![CDATA[viable]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9586</guid>
		<description><![CDATA[On May 24, 2019, Novartis announced the US-FDA approval of ‘the first and only gene therapy’ – Zolgensma, for a type of Spinal Muscular Atrophy (SMA), a lifesaving treatment for infants of less than 2 years of age. This unique drug halts disease progression &#8230; <a href="http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gene-therapy-price-commercial-viability-and-moral-dilemma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating ‘Shared Value’ in Pharma – The Way Forward</title>
		<link>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-shared-value-in-pharma-the-way-forward</link>
		<comments>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/#comments</comments>
		<pubDate>Mon, 30 Jul 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Arogya]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Parivar]]></category>
		<category><![CDATA[philanthropy]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[shared]]></category>
		<category><![CDATA[social responsibility]]></category>
		<category><![CDATA[social. society]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9079</guid>
		<description><![CDATA[Many Pharmaceutical companies, both global and local, are struggling with a plethora of critical challenges. With the industry reputation diving south successful navigation through this headwind has become an onerous task, more than ever before. Under this backdrop, the article, &#8230; <a href="http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Organic and Inorganic Growth Strategy For Sustainable Business Excellence</title>
		<link>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=organic-and-inorganic-growth-strategy-for-sustainable-business-excellence</link>
		<comments>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/#comments</comments>
		<pubDate>Mon, 30 Apr 2018 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[organic]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8936</guid>
		<description><![CDATA[For an enthusiast, witnessing any organization growing consistently, is indeed exhilarating. This becomes even more interesting at a time when challenges and frequent surprises in the business environment become a new normal. A robust short, medium and long growth strategy &#8230; <a href="http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MDGs Break Ground For SDGs: Is India Poised To Achieve The Health Goals?</title>
		<link>http://www.tapanray.in/mdgs-break-ground-for-sdgs-is-india-poised-to-achieve-the-health-goals/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mdgs-break-ground-for-sdgs-is-india-poised-to-achieve-the-health-goals</link>
		<comments>http://www.tapanray.in/mdgs-break-ground-for-sdgs-is-india-poised-to-achieve-the-health-goals/#comments</comments>
		<pubDate>Mon, 03 Apr 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[goals]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[IMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infant]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[maternal]]></category>
		<category><![CDATA[MDG]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Millenium]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[non-communicable]]></category>
		<category><![CDATA[poised]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[rate]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SDG]]></category>
		<category><![CDATA[SDG 3]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[U5MR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8170</guid>
		<description><![CDATA[The Millennium Development Goals (MDGs) were placed in the pages of history amid several other remarkable global initiatives of the United Nations (UN), as the timeframe for achievement of these targets got over in 2015. In 2000, the leaders of &#8230; <a href="http://www.tapanray.in/mdgs-break-ground-for-sdgs-is-india-poised-to-achieve-the-health-goals/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mdgs-break-ground-for-sdgs-is-india-poised-to-achieve-the-health-goals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mental Health Problem: A Growing Concern In The Healthcare Space Of India</title>
		<link>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india</link>
		<comments>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/#comments</comments>
		<pubDate>Mon, 16 Jan 2017 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[anxiety]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[Development Goals]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lok]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Rajya]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sabha]]></category>
		<category><![CDATA[SDG]]></category>
		<category><![CDATA[series]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8049</guid>
		<description><![CDATA[A thud! Something fell from high above! In no time, a bright young life of just a 32-year-old highly accomplished professional &#8211; a widely admired soul, vanished in the thin year, for good, mostly unnoticed in the quiet neighborhood, initially. &#8230; <a href="http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
